Drug Trial Radar · NCT07247162
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
63
Planned (sponsor's estimate)
Start
Aug 26, 2026
Primary completion
May 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- RECORDATI GROUPIndustry
- Sponsor type
- Industry
- First posted
- Nov 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.
Conditions
- Hypertension
- Hypercortisolemia
- Cushing Syndrome
Interventions
OsilodrostatDrug
Osilodrostat tablets 1 mg and 5 mg for oral useOsilodrostat tablets 1 mg and 5 mg for oral use.During the 18-week titration phase, the dose of the medication will be titrated every 3 weeks based on the cortisolaemic and clinical response to treatment. An independent endocrinologist titration committee will be applied to provide recommendations on dose-titration based on biochemical and clinical response. At the end of the 18-week dose titration phase, participants will enter a 12-week dose maintenance phase, which is also blinded. They will continue with the dose they were receiving at the end of the dose titration phase, unless there is a need to down-titrate or to stop the study medication for safety purposes.
PlaceboDrug
matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the efficacy of osilodrostat on the proportion of participants with normalization of urinary-free cortisol (UFC)Time frame: 30 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
NOLA Care, LLC
Jacksonville, Florida · Recruiting
Diabetes And Endocrinology Associates Of Stark County, Inc.
Canton, Ohio · Recruiting
Texas Valley Clinical Research
Weslaco, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.